ICER to review pricing of pipeline hopes of pharma majors

1 November 2018

The USA's Institute for Clinical and Economic Review (ICER) is to consider what might constitute a fair price for two drug candidates that are of great importance to the companies developing them.

Janssen, part of the US healthcare giant Johnson & Johnson (NYSE: JNJ), is hoping that esketamine will provide the first new mechanism of action to treat depression in 30 years, while Swiss pharma giant Novartis’ (NOVN: VX) siponimod is a multiple sclerosis (MS) candidate that is known to cross the blood-brain barrier.

Both drugs look likely to win US approval in 2019, and their sales performance could have a major impact on their respective companies’ future revenues.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK